Key Points
- CEO Fred Aslan sold 23,429 Artiva Biotherapeutics shares at an average price of $10.92, generating $255,844.68. He retained 1,449,765 shares, reducing his ownership by 1.59%.
- Artiva shares opened at $10.79, with a market capitalization of approximately $527.5 million. The stock has traded between $2.22 and $14.53 over the past year, while the company reported a quarterly loss of $0.63 per share.
- Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $39 target price, despite one sell rating. Several institutional investors, including 5AM Venture Management, BlackRock and Citadel Advisors, have recently initiated or expanded positions.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $10.92, for a total value of $255,844.68. Following the completion of the sale, the chief executive officer owned 1,449,765 shares in the company, valued at approximately $15,831,433.80. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Artiva Biotherapeutics Price Performance
Shares of Artiva Biotherapeutics stock opened at $10.79 on Thursday. The business has a 50 day simple moving average of $10.64 and a two-hundred day simple moving average of $8.92. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53. The stock has a market capitalization of $527.52 million, a P/E ratio of -3.27 and a beta of 2.18.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). As a group, research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Wall Street Zen raised Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Finally, Needham & Company LLC reissued a "buy" rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $39.00.
Check Out Our Latest Report on Artiva Biotherapeutics
Institutional Trading of Artiva Biotherapeutics
Several hedge funds have recently made changes to their positions in ARTV. 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $22,827,049. Blue Owl Capital Holdings LP acquired a new position in Artiva Biotherapeutics in the second quarter valued at approximately $8,483,000. Citadel Advisors LLC grew its position in Artiva Biotherapeutics by 419.3% in the third quarter. Citadel Advisors LLC now owns 798,397 shares of the company's stock worth $2,291,000 after acquiring an additional 644,658 shares during the period. BlackRock Inc. purchased a new position in Artiva Biotherapeutics in the second quarter worth approximately $6,739,000. Finally, Nantahala Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the second quarter worth $2,910,000.
About Artiva Biotherapeutics
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
